Search

The unique properties and sustainability advantages of sulfur polymer cement have led to efforts to use them as alternatives to traditional Portland cement. The current study explores the impact of environmental stresses on the strength development of polymer composite SunBG90, a material composed of animal and plant fats/oils vulcanized with 90 wt. % sulfur. The environmental stresses investigated include low temperature (−25 °C), high temperature (40 °C), and submersion in water, hexanes, or aqueous solutions containing strong electrolyte, strong acid, or strong base. Samples were analyzed for the extent to which exposure to these stresses influenced the thermo-morphological properties and the compressional strength of the materials compared to identical materials allowed to develop strength at room temperature. Differential scanning calorimetry (DSC) analysis revealed distinct thermos-morphological transitions in stressed samples and the notable formation of metastable γ-sulfur in hexane-exposed specimens. Powder X-ray diffraction confirmed that the crystalline domains identified by DSC were primarily γ-sulfur, with ~5% contribution of γ-sulfur in hexane-exposed samples. Compressive strength testing revealed high strength retention other than aging at elevated temperatures, which led to ~50% loss of strength. These findings reveal influences on the strength development of SunBG90, lending important insight into possible use as an alternative to OPC.

Summary: Background: Pulmonary fibrosis is characterized by lung parenchymal destruction and can increase morbidity and mortality. Pulmonary fibrosis commonly occurs following hospitalization for SARS-CoV-2 infection. As there are medications that modify pulmonary fibrosis risk, we investigated whether distinct pharmacotherapies (amiodarone, cancer chemotherapy, corticosteroids, and rituximab) are associated with differences in post-COVID-19 pulmonary fibrosis incidence. Methods: We used the National COVID-19 Cohort Collaboration (N3C) Data Enclave, which aggregates and harmonizes COVID-19 data across the United States, to assess pulmonary fibrosis incidence documented at least 60 days after COVID-19 diagnosis among adults hospitalized between January 1st, 2020 and July 6th, 2022 without pre-existing pulmonary fibrosis. We used propensity scores to match pre-COVID-19 drug-exposed and unexposed cohorts (1:1) based on covariates with known influence on pulmonary fibrosis incidence, and estimated the association of drug exposure with risk for post-COVID-19 pulmonary fibrosis. Sensitivity analyses considered pulmonary fibrosis incidence documented at least 30- or 90-days post-hospitalization and pulmonary fibrosis incidence in the COVID-19-negative N3C population. Findings: Among 5,923,394 patients with COVID-19, we analyzed 452,951 hospitalized adults, among whom pulmonary fibrosis incidence was 1.1 per 100-person-years. 277,984 hospitalized adults with COVID-19 were included in our primary analysis, among whom all drug exposed cohorts were well-matched to unexposed cohorts (standardized mean differences

Here, via applying metagenomics and metabolomics analyses, the authors show that fecal microbiota composition and microbiota-derived metabolites predict the trajectory of respiratory function and death in patients with severe SARS-Cov-2 infection, suggesting the gut-lung axis to play an important role in the recovery from COVID-19.